Paradoxically, melanoma composes a small minority of all skin cancer cases seen in the United States but accounts for most skin cancer deaths. 3 The continuing rise in melanoma mortality in the United States is disconcerting considering a decline in death rates for most solid tumors from 1975 through 2013. The cumulative incidence of melanoma in the US white population aged 0 to 74 years ranks third worldwide behind Australia and New Zealand. 4 Evidenced-based guidelines worldwide have not recommended routine screening for any type of skin cancer in the general population. Can thinking beyond these guidelines cultivate a benefit for a cancer with such a requisite for enhanced outcomes?
Visual whole-body skin examination is the most common method for skin cancer screening performed by primary care physicians. However, high-quality evidence has not supported routine skin examination for early detection of skin cancer in the general population. The US Preventive Services Task Force (USPSTF) update in 2016 maintained that the current existing evidence is "insufficient to examine the benefits versus harms of whole-body skin cancer screenings in asymptomatic adults." 5,p429 Are there other ways to examine the evidence that may lend an opportunity to improve early detection and mortality of malignant melanoma? Despite having a much lower nationwide incidence of melanoma, Canada has recently adopted the same melanoma management guidelines as practiced in Australia and New Zealand. 6, 7 These guidelines contain the recommendations of identifying and managing patients at high risk for future melanoma through clinical assessment. These risks include a person's age and sex, history of previous melanoma and nonmelanoma skin cancer; family history of melanoma, number of nevi (common and atypical), skin and hair pigment, response to sun exposure, and evidence of actinic skin damage. Evidence grade B, which represents a body of evidence that can be trusted to guide practice in most situations, has been designated for this recommendation. We believe that these recommendations can be applied to the implementation of research aimed at expanding the evidence base. The USPSTF agrees that targeted research among populations with the highest burden of disease would be useful. 5 However, until clear evidence to support screening is available, stemming the tide of the unfavorable epidemiology of malignant melanoma in the United States may remain a challenge. An opportunity for improving early detection by screening highrisk patients may exist.
Improvements in melanoma mortality results may be realized by enhancing primary prevention and early detection of disease. For achieving success in lowering cancer mortality, current screening practices are highly dependent on evidence-based guidelines from the USPSTF and other organizations. Screening rates for breast, cervix, endometrial, and colorectal cancers far exceed those for malignant melanoma as a possible reflection of more favorable guidelines. The incidence and death rates of melanoma compare closely with those of the combination of cervical and endometrial cancers. The yearly incidence of melanoma in both sexes and all races is only 20% lower than for cancers of the colon and rectum. 8 These comparisons highlight the importance of melanoma as a public health concern. Less than 25% of Americans reported receiving a skin examination in several studies, representing another opportunity for further improvement. 9 Managing malignant melanoma can be a major public health expense. This disease represents one of the most costly US cancers, with the annual cost of treatment increasing 288% from 2002 to 2011, to $3.35 billion. 10 During this period, the average annual cost of all other cancers increased by only 25%. This rise in the cost of melanoma is slightly higher than the 1.88-fold increase in the number of adults treated annually for this disease during this same period. New treatments, which have resulted in improved survival rates for patients with even more advanced melanoma, may account for a large portion of the increased costs. Accordingly, at least a portion of the incremental costs may have a survival benefit and improve the unfavorable years per life lost for this cancer. Regardless of the cause of these economics, costeffectiveness and feasibility of screening in primary care practices bear an even greater burden. Favorable cost-effectiveness of melanoma screening has been reported in the United States. Losina et al 11 found favorable cost-effectiveness in 1-time screening for patients older than 50 years and every 2 years for siblings of patients with melanoma. These findings compare similarly with other cancer screening programs in the United States; however, much less data are available for melanoma. Primary prevention may also have benefit and favorable cost-effectiveness. In an economic evaluation, the Australian skin cancer prevention initiative, called SunSmart, was found to be an intervention for which every dollar invested would return an estimated A$2.30. 12 In contrast, these authors concluded in this investigation that the health gains of cervical cancer screening, cervical cancer prevention, colorectal cancer screening, and breast cancer screening all come at a cost in Australia.
Evidence to Support Screening
Regarding melanoma screening, the imperative question is whether implementation can improve early detection and, most importantly, mortality. Tumor thickness and regional spread at the time of diagnosis are well established as the most important predictors of melanoma mortality. In several case-control and population-based trials, physician-based screening increased the detection of thinner melanomas; we summarize the results of these trials in the following paragraphs and in the Table. A workplace case-control study was conducted at the California-based Lawrence Livermore National Laboratory from 1969 through 1996 and comprised 3 phases: pre-awareness, a community-based melanoma educational campaign, and a skin screening program. 13 The crude incidence of melanoma thicker than 0.75 mm decreased during the 3 periods from 22.1 to 15.3 to 4.62 per 100,000 personyears (P¼.001) compared with statewide cancer statistics. Most noteworthy, the largest decrease was seen in the physician screening program. No mortality was observed in the screening period; the expected number of deaths was 3.39 (P¼.03). A 2010 Australian, population-based, case-controlled study found that whole-body physician skin examination was associated with a 14% lower chance of being diagnosed as having a melanoma thicker than 0.75 mm and a 40% lower chance for those larger than 3 mm.
14 In 2012, Swetter et al 15 also found that whole-body physician skin examination detected thinner melanomas, especially in men older than 60 years (odds ratio, 4.09; 95% CI, 1.88-8.99).
Reducing melanoma mortality from screening remains an unanswered question. In 2003, implementation was begun on the Skin Cancer Research to Provide Evidence for Effectiveness of Screening in Northern Germany (SCREEN) project. 16 The pilot phase began with a 2-year public awareness campaign and an 8-hour physician training course in skin cancer detection. Residents of Germany's most northern state, SchleswigHolstein (N¼1.9 million), were eligible to participate in screening; 360,288 patients (19%) received a visual whole-body skin examination performed by a physician chosen by the participants. Seventy-seven percent of patients (278,741) in the study group were initially evaluated by primary care physicians who completed the training course, and the remainder were evaluated by a dermatologist based on skin cancer risk factors. Data collected 5 years after study inception revealed a 48% reduction in melanoma mortality for the screened group compared with a matched unscreened control group from another locale in Germany. Melanoma detection was 90% for cancers smaller than 1.0 mm. For the detection of 1 melanoma, 620 persons needed to be screened. Biopsies were performed in 50 persons to detect 1 melanoma in men aged 20 to 49 years, with the number dropping to 20 persons for men older than 65 years. The second arm of the SCREEN project involved screening 28 million patients older than 35 years in the rest of Germany from 2008 through 2013. In contrast to the pilot phase, the mortality benefit was not sustained in this second phase of the project. 17 Larger sample size, higher participation rates, and the lack of a public awareness campaign are possible explanations for the disparate results. Despite these findings, Germany has adopted nationwide skin cancer screening every 2 years for all citizens older than 35 years. Granting the disappointing results from the second phase of the SCREEN project, some believe that the results of the pilot phase of SCREEN may demonstrate a proof of concept that comprehensive, multidimensional screening initiatives could reduce the burden of melanoma. 18 Before we outline a plan for skin cancer screening, we should address the potential for harm. The whole-body skin examination is noninvasive and requires little, if any, preparation; however, potential harms do exist. A current study at the University of Pittsburgh is evaluating screening-related harms due to overdiagnosis, procedure-related adverse effects, and psychological harms. 19 We are not aware of any previous studies that specifically evaluated the harms related to skin cancer screening. 20 We recognize that the evaluation of potential harms is especially important regarding any intervention that screens for the presence of diseases. The results of this study may have a large effect on the future direction of screening practices for melanoma.
The USPSTF did discuss the concern regarding the number of biopsies needed to diagnosis a skin cancer in the SCREEN program, which we discussed previously in this section. 5 Dermoscopy may further lower the risk of potential harm by improving the accuracy of diagnosis and reducing the number of excisions of benign lesions. 21 Although dermoscopy is most commonly used by dermatologists, primary care physicians in this study were able to improve their sensitivity for the diagnosis of melanoma while also reducing the number of excisions of benign lesions.
Plan of Action
The burden rests on the shoulders of primary care physicians. There is approximately 1 dermatologist for every 30,000 patients in the United States. 22 A combined effort between primary care and dermatology is necessary to improve screening rates and mortality. Lack of time and lack of training in skin cancer examination (SCE) have been identified as barriers to screening. 23 A 2009 survey study of 4 US residency programs included questionnaires from 94.1% of residents in primary care tracks. During residency, 75.8% were never trained in SCE; 55.3% never observed an SCE; and only 15.9% reported being skilled in SCE. 24 We advocate improved education on SCE in primary care residency training programs as a means to improve screening rates. The development of a formal dermatology curriculum, both reproducible and generalizable, may be the foundation for heightened early detection. The American Academy of Dermatology has developed a Basic Dermatology Curriculum composed of 48 learning modules that are freely accessible on their website. 25 More specific to skin cancer is the Internet Curriculum for Melanoma Early Detection (INFORMED). 26 These are excellent resources that we have integrated into our internal medicine residency curriculum. Although decisive conclusions about screening outcomes are currently unavailable, changes in dermatology education to enhance SCE skills for physicians training in primary care are an important step in the path to successful screening.
Conclusion
Current and future advances in melanoma treatment may have major potential to improve outcomes; however, we believe that prevention and early detection need further attention to make the largest mortality impact. Ethical implications and design limitations contribute to the lack of high-quality evidence from randomized studies evaluating the efficacy of cancer screening. Until the evidence base for melanoma screening is further expanded, we propose that a heightened focus is necessary for patients with the highest risk of this disease. White men older than 50 years have a higher risk of dying of this disease, and risk in this group continues to increase with age. This group of men averages 3 to 4 visits to their primary care doctors annually, providing an opportunity for skin cancer screenings. Other well-established risk factors, such as lighter skin pigmentation, sunburns, indoor tanning bed exposure, personal and family history of melanoma, personal history of nonmelanoma skin cancer, multiple nevi, and evolving nevi, should also warrant more frequent skin examinations.
In 2016, US President Barack Obama launched a national cancer initiative program known as the Cancer Moonshot Task Force. The Moonshot Program, developed at The University of Texas MD Anderson Cancer Center, includes goals for initial screenings and the development of early treatments for some of the deadliest cancers. Patients surveyed in this program ranked melanoma second in importance. Although the USPSTF has not found sufficient evidence to advocate for widespread melanoma screening, we have identified other pathways to improving outcomes for malignant melanoma. Primary prevention through public awareness and education has been found to be a pathway for success. Educating primary care residents and primary care physicians on skin cancer evaluation is recommended for improving early detection. A concerted effort between primary care and dermatology is vital to realize advancements in this difficult public health problem. The challenge we support is an opportunity to change current practices to affect the burden of disease. For malignant melanoma, now is the time for change.
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